Sickle Cell Disease

Negative perceptions of care in the ED setting appeared to be a barrier to seeking care among adolescents and adults with sickle cell disease, according to results of a prospective survey-based study published in JAMA Network Open.

Escalated dosing of hydroxyurea had greater clinical efficacy than fixed dosing of the drug for children with sickle cell disease in sub-Saharan Africa, according to randomized study results published in The New England Journal of Medicine.

World Sickle Cell Day is held every June 19.

LentiGlobin gene therapy led to reductions in sickle cell disease-related complications and hemolysis, according to results of a phase 1/phase 2 trial presented at the virtual American Society of Gene and Cell Therapy Annual Meeting.

The COVID-19 pandemic continues to affect the lives of individuals from across the globe. In this episode, Kelly Cawcutt, MD, an assistant professor of medicine and board-certified infectious disease and critical care physician at the University of Nebraska Medical Center, shares her expertise on the ongoing pandemic and its impact on health care.

Global Blood Therapeutics committed $250,000 to support the sickle cell disease community during the COVID-19 pandemic.

Acute and chronic complications of sickle cell disease necessitate frequent interaction with the medical system.

ORLANDO — LentiGlobin gene therapy led to substantial reductions of sickle hemoglobin and considerable improvement in key markers of hemolysis, according to updated results from the phase 1/phase 2 HGB-206 study presented at TCT | Transplantation & Cellular Therapy Meetings.

Sickle cell disease, the most common inherited red blood cell disorder in the United States, is associated with debilitating physical symptoms, including acute pain crises, joint and organ damage, diminished cognitive function and decreased life expectancy.

The FDA granted rare pediatric disease designation to ARU-1801, an investigational autologous gene therapy, for the treatment of sickle cell disease, according to the agent’s manufacturer.